Barrette S, Orlic D
Hematopoiesis Section/NHGRI/NIH, Building 49, 49 Convent Drive, Bethesda, MD 20892, USA.
Curr Opin Mol Ther. 2000 Oct;2(5):507-14.
The hematopoietic stem cell is the target for gene therapy of human blood disease. Low retroviral receptors for the commonly used vectors and quiescence of hematopoietic stem cells are believed to be major obstacles to the success of gene therapy. The development of new stem cell assays has allowed better understanding of the biology and phenotype of hematopoietic stem cells, leading to selection of highly enriched populations of hematopoietic stem cells. Quantitation of retrovirus receptors on these enriched populations of hematopoietic stem cells has resulted in the identification of subpopulations of cells expressing high levels of retrovirus receptors. New promising retrovirus envelopes are being developed. In this review, we discuss those issues that may help to resolve the problem of low gene transfer efficiency into human hematopoietic stem cells.
造血干细胞是人类血液疾病基因治疗的靶点。人们认为,常用载体的逆转录病毒受体水平较低以及造血干细胞的静止状态是基因治疗成功的主要障碍。新的干细胞检测方法的发展使人们能够更好地了解造血干细胞的生物学特性和表型,从而筛选出高度富集的造血干细胞群体。对这些富集的造血干细胞群体上的逆转录病毒受体进行定量分析,已鉴定出表达高水平逆转录病毒受体的细胞亚群。新型有前景的逆转录病毒包膜正在研发中。在本综述中,我们讨论了那些可能有助于解决向人类造血干细胞基因转移效率低下问题的相关事宜。